Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.

Okumura S, Sakakibara M, Hayashida R, Jinno Y, Tanaka A, Okada K, Hayashi M, Ishii H, Murohara T.

Heart Vessels. 2014 Jan;29(1):7-14. doi: 10.1007/s00380-012-0321-y. Epub 2013 Jan 29.

PMID:
23358876
2.

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators.

Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025. Epub 2009 Feb 11.

PMID:
19216014
3.

Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS).

Ota T, Ishii H, Suzuki S, Shibata Y, Tatami Y, Harata S, Shimbo Y, Takayama Y, Tanaka A, Kawamura Y, Osugi N, Maeda K, Kondo T, Murohara T.

Atherosclerosis. 2015 Sep;242(1):155-60. doi: 10.1016/j.atherosclerosis.2015.07.012. Epub 2015 Jul 9.

PMID:
26188539
4.

Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.

Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.

Eur J Intern Med. 2009 Mar;20(2):197-200. doi: 10.1016/j.ejim.2008.06.009. Epub 2008 Aug 15.

PMID:
19327612
5.

The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction.

Celik T, Kursaklioglu H, Iyisoy A, Kose S, Kilic S, Amasyali B, Kardesoglu E, Isik E.

Coron Artery Dis. 2005 Aug;16(5):321-6.

PMID:
16000891
6.

Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.

Ogita M, Miyauchi K, Miyazaki T, Naito R, Konishi H, Tsuboi S, Dohi T, Kasai T, Yokoyama T, Okazaki S, Kurata T, Daida H.

Heart Vessels. 2014 Jan;29(1):35-41. doi: 10.1007/s00380-013-0330-5. Epub 2013 Mar 21.

PMID:
23516028
7.

Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.

Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.

Transplant Proc. 2005 Nov;37(9):3808-12.

PMID:
16386546
8.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators.

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
9.

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.

Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, Yasuno S, Fujimoto A, Tanaka S, Kimura G, Nakao K.

Clin Exp Nephrol. 2013 Apr;17(2):211-7. doi: 10.1007/s10157-012-0676-5. Epub 2012 Sep 6.

PMID:
22948416
10.

Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).

Goodman SG, Langer A, Bastien NR, McPherson R, Francis GA, Genest JJ Jr, Leiter LA; DYSIS Canadian Investigators.

Can J Cardiol. 2010 Nov;26(9):e330-5.

11.
12.
13.

High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention.

Sattler KJ, Herrmann J, Yün S, Lehmann N, Wang Z, Heusch G, Sack S, Erbel R, Levkau B.

Eur Heart J. 2009 Aug;30(15):1894-902. doi: 10.1093/eurheartj/ehp183. Epub 2009 May 27.

PMID:
19474052
14.

Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on renal function in patients with ST-segment elevation myocardial infarction treated with primary or rescue percutaneous coronary intervention.

Osherov AB, Roguin A, Aronson D, Grenadier E, Kerner A, Boulus M, Kapeliovich M, Hani A, Hammerman H, Beyar R, Nikolsky E.

EuroIntervention. 2009 Nov;5(5):604-9.

PMID:
20142182
15.

The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.

Kanadaşi M, Cayli M, Demirtaş M, Inal T, Demir M, Koç M, Avkaroğullari M, Dönmez Y, Usal A, Alhan CC, San M.

Heart Vessels. 2006 Sep;21(5):291-7. Epub 2006 Sep 29.

PMID:
17151816
16.

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators.

Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. Epub 2007 Oct 17.

17.
18.

Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk.

Boh M, Opolski G, Poredos P, Ceska R, Jezovnik M.

Int Angiol. 2011 Aug;30(4):366-74.

PMID:
21747355
19.

Impact of low level of high-density lipoprotein-cholesterol sampled in overnight fasting state on the clinical outcomes in patients with acute myocardial infarction (difference between ST-segment and non-ST-segment-elevation myocardial infarction).

Ji MS, Jeong MH, Ahn YK, Kim YJ, Chae SC, Hong TJ, Seong IW, Chae JK, Kim CJ, Cho MC, Rha SW, Bae JH, Seung KB, Park SJ; Korea Acute Myocardial Infarction Registry Investigators.

J Cardiol. 2015 Jan;65(1):63-70. doi: 10.1016/j.jjcc.2014.04.002. Epub 2014 Sep 18.

20.

Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.

Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators.

J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052. Retraction in: J Am Coll Cardiol. 2013 Apr 23;61(16):1750.

Supplemental Content

Support Center